Open Orphan PLC DNDi Phase II trial support
29 Julio 2021 - 1:00AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
29 July 2021
29 July 2021
Open Orphan plc
("Open Orphan" or the "Company")
Contract to support Phase II river blindness drug trial
Antibiotic drug study for the treatment of the second-most
common cause of blindness due to infection
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
clinical research organisation (CRO) which is the world leader in
testing vaccines and antivirals using human challenge clinical
trials, announces a contract to supply consultancy services to
support a Phase II trial in Onchocerciasis Disease, an infectious
disease commonly known as river blindness.
Venn Life Sciences ("Venn") , a subsidiary of Open Orphan, will
provide Data Management & Biostatistics services to support the
Phase II trial of an antibiotic drug candidate for Drugs for
Neglected Diseases initiative ("DNDi"), a not-for-profit research
organisation developing new affordable and patient-friendly
treatments for neglected patients around the world. DNDi was
founded in 2003 by Médecins Sans Frontières, the World Health
Organisation, and five international research institutions.
The Venn team in the Paris office will provide support for the
trial, taking place in the Democratic Republic of Congo, to
evaluate the product ABBV-4083, owned by AbbVie and licensed to
DNDi, as a potential antibiotic treatment for patients with
Onchocerciasis, the second-most common cause of blindness due to
infection, after trachoma. ABBV-4083 was identified by a screening
of anti-infective compounds led by the pharmaceutical company
AbbVie and the anti-Wolbachia consortium A-WOL at the Liverpool
School of Tropical Medicine. The study has already commenced.
Venn offers a unique set of high quality, innovative,
methodology, data management and biostatistics services utilising
the very best technologies and clinical trial expertise to help
their clients have access to their data faster and at a lower cost.
Venn's portfolio of services range from design conception, through
to data-acquisition and management activities to the analysis,
reporting and exploitation of the results and their subsequent
presentation for submission to the appropriate regulatory
authorities and/or publication. Venn offer a fully standardised and
compliant methodology for collating, validating and presenting
real-time information to their clinical partners.
Cathal Friel, Executive Chairman of Open Orphan, said: "We are
delighted to announce another contract win for the business which
underpins our confidence in the continued growth we expect to see
in 2021. Our teams have a unique knowledge of multiple clinical
data management systems and our team of biostatisticians have
extensive experience to bring to bear on such studies. We're very
proud to be working with DNDi to support their development of what
could be a game-changing drug to help people affected by river
blindness in some of the world's poorest nations."
Sabine Specht, Head of the Filarial Clinical Programme at DNDi,
said: "We are delighted that Open Orphan has joined DNDi, AbbVie
and multiple partners involved in the development of ABBV-4083 for
those at risk or suffering from onchocerciasis. The Democratic
Republic of Congo is one of the most affected countries by this
debilitating disease, so it is especially important that our
clinical trials will take place there, where we will be working
with national authorities to test out this potentially innovative
treatment."
For further information please contact
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser and Joint
Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Richard Johnson / Oscair
McGrath
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard Chambers
Davy (Euronext Growth Adviser and Joint Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & +44 (0)20 7933 8780 or openorphan@walbrookpr.com
IR)
Paul McManus / Louis Ashe-Jepson +44 (0)7980 541 893 / 07747 515 393
/ Sam Allen / 07502 558 258
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
pharmaceutical service/contract research company that is a world
leader in testing vaccines and antivirals using human challenge
clinical trials. The company provides services to Big Pharma,
biotech and government/public health organisations.
Open Orphan runs challenge studies in London from both its
19-bedroom Whitechapel quarantine clinic, opened in February 2021,
and its 24-bedroom QMB clinic with its highly specialised on-site
virology and immunology laboratory. Open Orphan has a leading
portfolio of eight human challenge study models for infectious and
respiratory diseases and is developing a number of other models
including the world's first COVID-19 human challenge study model as
part of the Human Challenge Programme .
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological and digital (wearable) biomarkers. The
Disease in Motion platform has many potential applications across a
wide variety of end users including big technology, wearables,
pharma and biotech companies. Following COVID-19 there is now a
renewed interest and investment in infectious diseases.
Open Orphan's Paris office has been providing biometry, data
management and statistics to its many European pharmaceutical
clients for over 20 years. For over 15 years, the Company's
Netherlands office has been providing drug development consultancy
and services, including CMC (chemistry, manufacturing and
controls), PK and medical writing, to a broad range of European
clients. Both offices are now also fully integrated with the London
office and working on challenge study contracts as well as
supporting third party trial contracts .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADKFBKOBKDPOB
(END) Dow Jones Newswires
July 29, 2021 02:00 ET (06:00 GMT)
Venn Life Sciences (LSE:VENN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Venn Life Sciences (LSE:VENN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024